Ipca Labs
Jun 22, 2017
Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports
Novartis takes on Regeneron with AMD drug that needs fewer doses than Eylea Last year, U.S. sales of Regeneron’s drug to treat age-related macular degeneration (AMD) came in at $3.3 billion—68% of the company’s total revenues—so it’s no wonder investors have been expressing some concerns about potential rivals movin...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
